samedan logo
 
 
 
spacer
home > ebr > winter 2017 > super screening
PUBLICATIONS
European Biopharmaceutical Review

Super Screening

To fully understand the details of a biological mechanism at the molecular level, it is important to characterise the biomolecular interaction in a relevant environment without modifying the samples or applying purification procedures.

Enabling this is the advent of a robust and easy-to-use fluidic system, and the injection of complex samples without dilution – such as serum, plasma, cell supernatants or even lysates – is no longer an issue for diagnostic research or drug screening. Moreover, crude samples can also be immobilised on the sensor chip for a rapid and high-throughput quantification that can be utilised in pharmaceutical R&D. The immobilised biological molecules may be quantified in different crude supernatants with only a single injection of the target.

The following discussion examines a biomarker – which we will call ‘Protein Y’ (PY) – which is a component of the HIV structure. This protein is commonly employed as an AIDS diagnosis tool in combination with other immunological tests. Until recently, enzyme-linked immunosorbent assay (ELISA) has been the standard method for PYbased diagnoses. Nevertheless, this method shows some limitations in terms of rapidity and high-throughput, which are increasingly required in pharma R&D. Now, however, there is a good alternative to the use of ELISA in determining the protein concentration. Unlike ELISA – which needs labelling and is time-consuming – surface plasmon resonance imaging (SPRi) is label-free and takes only a few minutes to screen a huge panel of samples.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Fatima-Ezzahra Hibti joined Genoptic – which later became HORIBA Scientific – as Application Engineer in 2009 after graduating from the Université de Reims Champagne- Ardenne, France, with a Master’s degree in Biotechnology and Therapeutic Strategies. For more than seven years, she was involved in various national and European projects and is now in charge of customer feasibility experiments. Fatima-Ezzahra is currently working with the life sciences team to develop the SPRi platform, as well as new applications for it in collaboration with the SPRi team and external partners.

Dr Chiraz Frydman is the Product Manager of Life Science Instruments at HORIBA Scientific. In 1996, she received her engineering diploma in Biology and an MSc in Applied Chemistry and Industrial Process Engineering the following year. After completing her PhD in Enzymatic Engineering, Bioconversion and Microbiology, Chiraz set up her own company dedicated to developing immune-affinity kits. Following this, she worked as a Biophotonic Project Manager at Opticsvalley.

spacer
Fatima-Ezzahra Hibti
spacer
spacer
spacer
Dr Chiraz Frydman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Memo Therapeutics AG collaborate on the fast-track manufacturing of a SARS-CoV-2- neutralizing antibody for the therapy of COVID-19

Vilnius, Lithuania, and Schlieren, Switzerland – August 11, 2020 – Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG (MTx), announce a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a 4-month fast-track process approved by regulatory authorities.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement